IO Biotech, Inc. ceased operations and filed for Chapter 7 bankruptcy on March 31, 2026, following a review of strategic alternatives. This action will result in the liquidation of the company's assets, the appointment of a Chapter 7 trustee, and the termination of all employees and the board of directors. It is highly unlikely that common stock holders will receive any payment from the bankruptcy proceedings.

Ensysce Biosciences Inc. is exploring strategic alternatives for its business. To maintain enterprise value during this period, the company approved retention packages for three managers and its Chief Financial Officer, totaling approximately $205,475. Board member Lee Rauch resigned, citing disagreement with these compensation packages and prior board actions.

Werewolf Therapeutics, Inc. announced its financial results for the quarter ended December 31, 2025. The company is exploring strategic alternatives, including potential partnerships, to enhance stockholder value, manage its cash runway, and define timelines for preclinical and clinical development.

Genprex announced that its collaborators will present positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid) at the 2026 AACR Annual Meeting. The findings advance the understanding of TUSC2's therapeutic mechanisms in lung cancer and identify TROP2 and PTEN as potential biomarkers of resistance to TUSC2 gene therapy in non-small cell lung cancer, which could refine patient selection strategies.

Atara Biotherapeutics announced that a Type A meeting with the U.S. Food and Drug Administration (FDA) has been scheduled to discuss the Complete Response Letter (CRL) issued on January 9, 2026, for the Biologics License Application (BLA) of EBVALLO™. This meeting is a critical step for the company to address the FDA's concerns and determine the next steps for the drug's potential approval.

BioAtla announced a formal process to explore strategic alternatives, including asset sales and partnerships, and implemented a 70% workforce reduction to reduce costs. The company is also navigating an ongoing Nasdaq delisting review and is in discussions to revise a previously announced $40 million private placement. Concurrently, the Chief Financial Officer was replaced.

Werewolf Therapeutics, Inc. announced on February 24, 2026, its intention to explore strategic alternatives. The company has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in this strategic evaluation.

Genprex announced the issuance of patents in Japan and Europe for Reqorsa® Gene Therapy in combination with PD-L1 and PD-1 antibodies to treat cancer, bolstering its intellectual property portfolio. The company also provided an update on its Phase 1/2 Acclaim-3 clinical trial, which is evaluating REQORSA in combination with Genentech's Tecentriq for extensive stage small cell lung cancer, with interim analysis for the Phase 2 expansion expected in the second half of 2026.